Share capital [Text Block] | 9 Share capital Authorized: unlimited common shares, no par value Number of shares Ascribed value November 30, 2014 60,296,365 111,833 Issued pursuant to the Sunward Arrangement 43,116,312 22,851 Exercise of options 7,499 7 Exercise of Sunward Arrangement Options 347,999 177 Restricted Share Units 795,368 819 Deferred Share Units 232,878 353 November 30, 2015 104,796,421 136,040 Exercise of options 162,854 65 Restricted Share Units 108,399 34 Deferred Share Units 218,795 218 November 30, 2016 105,286,469 136,357 Exercise of options 188,856 85 Restricted Share Units 209,198 83 November 30, 2017, issued and outstanding 105,684,523 136,525 On April 30, 2012, under the NovaGold Arrangement, Trilogy committed to issue common shares to satisfy holders of NovaGold deferred share units (“NovaGold DSUs”), once vested, on record as of the close of business April 27, 2012. When vested, Trilogy committed to deliver one Common Share to the holder for every six shares of NovaGold the holder is entitled to receive, rounded down to the nearest whole number. As of November 30, 2017, 20,685 3,447 Refer to note 8 for a description of Common Shares issued pursuant to the Sunward Arrangement. All Sunward Arrangement Options have been exercised or expired. (a) Stock options The Company has a stock option plan providing for the issuance of options with a rolling maximum number equal to 10% of the issued and outstanding Common Shares at any given time. The Company may grant options to its directors, officers, employees and service providers. The exercise price of each option cannot be lower than the greater of market price or fair market value of the Common Shares (as such terms are defined in the plan) at the date of the option grant. The number of Common Shares optioned to any single optionee may not exceed 10 During the year ended November 30, 2017, 1,695,000 1,785,000 0.69 0.43 0.22 0.13 Assumptions used in the pricing model for the period are as provided below. November 30, 2017 November 30, 2016 November 30, 2015 Risk-free interest rates 0.90 % 0.52 % 0.42-1.12 % Exercise price CDN$0.69 CDN$0.43 CDN$0.55 Expected life 3.0 years 3.0 years 3.0 years Expected volatility 74.2 % 59.4 % 56.8-59.5 % Expected dividends Nil Nil Nil The Company recognized a stock option payment charge of $ 0.4 0.4 0.7 As of November 30, 2017, there were 993,342 0.65 0.05 November 30, 2017 Number of options Weighted average Balance beginning of year 6,049,433 0.50 Granted 1,695,000 0.55 Exercised (447,604) 0.46 Forfeited (169,329) 0.49 Balance end of year 7,127,500 0.54 Outstanding Exercisable Unvested Range of price Number of Weighted Weighted Number of Weighted Number of $0.33 to $0.50 4,242,500 2.70 0.40 3,975,831 0.41 266,669 $0.51 to $1.00 2,830,000 3.08 0.72 2,103,327 0.78 726,673 $1.01 to $1.54 55,000 0.42 1.54 55,000 1.54 - 7,127,500 2.84 0.54 6,134,158 0.54 993,342 The aggregate intrinsic value of vested share options (the market value less the exercise price) at November 30, 2017 was $ 1.8 0.6 0.2 0.1 (b) NovaGold Arrangement Options Under the NovaGold Arrangement, holders of NovaGold stock options received one option in Trilogy for every six options held in NovaGold (“NovaGold Arrangement Options”). All remaining NovaGold Arrangement Options expired unexercised during fiscal 2017. November 30, 2017 Number of options Weighted average Balance beginning of year 312,195 4.28 Expired (312,195) 4.28 Balance end of year - - (c) Restricted Share Units and Deferred Share Units The Company has a Restricted Share Unit Plan (“RSU Plan”) and a Non-Executive Director Deferred Share Unit Plan (“DSU Plan”) to provide long-term incentives to employees, officers and directors. The RSU Plan and DSU Plan may be settled in cash and/or Common Shares at the Company’s election with each RSU and DSU entitling the holder to receive one common share of the Company or equivalent value. All units are accounted for as equity-settled awards. On December 15, 2016, 600,000 115,841 Number of RSUs Number of DSUs Balance beginning of year 400,001 925,390 Granted 600,000 115,841 Vested/paid (399,999) - Balance end of year 600,002 1,041,231 For the year ended November 30, 2017, Trilogy recognized a stock-based compensation charge of $ 0.4 0.3 0.1 (d) Share Purchase Warrants Number of Weighted average Weighted average Balance beginning of year 6,521,740 2.60 1.60 Balance end of year 6,521,740 1.60 1.60 |